14 results about "Immunocompatibility" patented technology

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

The invention discloses injectable zwitterionic conductive hydrogel as well as a preparation method and application thereof. The hydrogel is formed by self-assembly of a zwitterionic copolymer and a PEDOT / PSS conductive polymer, the zwitterionic copolymer is sulfobetaine metacrylic acid ester or a copolymer formed by polymerizing sulfobetaine metacrylic acid ester and other comonomers. According to the invention, the zwitterionic copolymer containing sulfobetaine methacrylate and the PEDOT / PSS conductive polymer solution can be quickly self-assembled to form the hydrogel through simple mechanical mixing, and the hydrogel is endowed with excellent injectability and self-repairing performance based on the dynamic crosslinking characteristic of electrostatic interaction. The hydrogel has excellent immunocompatibility and conductivity, and can play a role in various application scenes of bioelectronics.

The invention belongs to the technical field of biological medicines, and particularly relates to a membrane-coated oncolytic virus as well as a preparation method and application thereof. The oncolytic virus contains a GSDMD N-terminal expression cassette regulated and controlled by a heated shock promoter, and pyroptosis can be induced under exogenous mild thermal stimulation, so that the virus is promoted to be quickly released, and reinfection and amplification of adjacent tumor cells are realized. A bionic nano-vesicle (iNV) formed by a donor cell membrane modified by genetic engineering is used as an outer layer to coat a genetically engineered oncolytic virus (GOV) to obtain a membrane-coated oncolytic virus iNV-GOV, so that the membrane-coated oncolytic virus iNV-GOV simultaneously has immunocompatibility and active tumor recognition capability, is suitable for solid tumors such as pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC) and the like, and can be used for preparing an anti-tumor drug. And the tumor volume can be obviously reduced in mouse in-vivo model experiments.

The invention relates to a self-drying gel. The self-drying gel is prepared from the following raw materials: cationic imidazolium salt, dopamine hydrochloride, a carboxyl ammonium zwitterionic monomer and carboxyl chitosan. The self-drying gel provided by the invention has the advantages of coating formation, in-situ self-drying, adhesion resistance, good biocompatibility and high immunocompatibility, so that secondary injury is not easily caused during clinical replacement, and wound repair can be promoted by adjusting immune response.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The invention discloses a functional decellularized porcine cornea, a decellularized porcine cornea composite scaffold containing layered slow-release bioactive molecules and a preparation method of the functional decellularized porcine cornea composite scaffold. The preparation method of the functionalized decellularized pig cornea comprises the following steps: (1) pretreating raw materials; (2) carrying out decellularization treatment; (3) carrying out functionalization treatment on the decellularized porcine cornea and the like. Researches show that the functionalized decellularized porcine cornea prepared by the method disclosed by the invention can well load bioactive molecules. In addition, the functionalized decellularized porcine cornea prepared by the method disclosed by the invention also has better mechanical properties. Furthermore, based on the functionalized decellularized porcine cornea, a layered sustained-release design and a 3D printing customization technology are adopted, the cornea scaffold with anti-inflammatory, regeneration promotion and neural restoration functions is constructed, breakthrough is achieved in the aspects of immune compatibility, mechanical properties and curative effect controllability, and an innovative solution is provided for cornea disease treatment.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof to provide immune compatible, allogeneic cell therapies. In the various aspects and embodiments, the cell populations and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the populations by gene editing, and methods for cell therapy involving cells or tissues derived from the cell populations (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

The present invention is directed at a method for treating biological tissue and a biological tissue obtained by the treatment method, and specifically at a method for treating biological tissue so as to suppress the calcification, risk of biofilm adherent over pericardium and strength reduction of the tissue due to treatment as well as to suppress immunogenic response or improve immunocompatibility of the biological tissue.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specific populations. In the various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the cell banks by gene editing, and methods for cell therapy involving cells or tissues derived from the cell banks (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

The application relates to the technical field of biomaterials, and discloses a conductive polymer with immunocompatibility, a monomer, a dispersion liquid, and a preparation method and application thereof. The conductive polymer has a structure as shown in formula A or formula B. Raw materials including a conductive polymer monomer, polystyrene sulfonic acid, an inorganic alkali, sodium persulfate and iron sulfate are dispersed in water, and then subjected to oxidation chemical polymerization at 0-50 DEG C for 12-36 h; after ion exchange resin is added for post-treatment, the conductive polymer dispersion liquid is obtained through suction filtration; and polystyrene sulfonic acid and water are removed through drying to obtain the conductive polymer. The material has excellent conductive performance, and after being prepared into a dispersion liquid and coated on the surface of a biological substrate, the material has a low inflammation and foreign body reaction level after being implanted in vivo, has long-term stability, and can be applied to coating materials of implantable bioelectronic devices.

The present invention relates to the technical field of medical materials. Disclosed is a surface treatment method for improving the immunocompatibility of an implantable medical device by means of silane coupling agent treatment. The silane coupling agent has the following structural formula, wherein R1, R2 and R3 are independently chlorine, hydroxyl, methyl, methoxy, ethoxy, or trimethylsiloxy; L is-(CH2)n-, wherein n is an integer from 0 to 15; and R4 is a sulfonic acid group, a methyl phosphonic acid group, a carboxyl group, or a monoglyceride group. It is found in the present invention that the silane coupling agent with this structure has an excellent anti-foreign body reaction effect and can be used for improving the immunocompatibility of the implantable medical device. The coupling agents with this structure are all existing mature finished products, which do not require further research and development in terms of synthetic preparation processes. The coupling agent can be used as a silane coupling agent material capable of quickly, simply, and conveniently performing surface grafting on biological materials and implantable medical instruments. After implantation, the corresponding product grafted with the silane coupling agent has a significantly improved immunocompatibility.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The present application relates to a self-drying gel, raw materials for preparing the self-drying gel comprising: a cationic imidazole salt, dopamine hydrochloride, a carboxybetaine zwitterionic monomer and carboxymethyl chitosan. The self-drying gel provided by the present application has the advantages of being capable of being coated and molded, self-drying in situ, anti-adhesion, good biocompatibility and high immunocompatibility, so that secondary injury is not easily caused during clinical replacement, and wound repair can be promoted by adjusting the immune response.

The present invention discloses a stem cell membrane-modified liposome nanoparticle and a preparation method thereof, belonging to the field of nano-drug delivery technology, and specifically relates to: a core layer, wherein the core layer is a carrier and a drug, the drug is loaded on the carrier, the carrier is a lipid carrier, and the lipid carrier includes egg phosphatidylcholine and cholesterol; a membrane layer, wherein the membrane layer is a stem cell membrane, and the stem cell membrane is coated on the outside of the core layer; an outer layer, wherein the outer layer includes a chitosan derivative; the core layer and the membrane layer constitute the stem cell membrane-coated liposome nanoparticle, and the amount of the chitosan derivative is 400-600wt% of the stem cell membrane-coated liposome nanoparticle. The present invention provides a stem cell membrane-modified liposome nanoparticle with good stability, good drug release effect in an acidic tumor microenvironment, good targeting, good immunocompatibility, good biosafety, and good biocompatibility, and a preparation method thereof.